FDA Expands Pembrolizumab Approval for Advanced Melanoma FDA Expands Pembrolizumab Approval for Advanced Melanoma

The expanded approval is for the adjuvant treatment of advanced melanoma after complete resection in patients aged 12 years and older.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news